HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US Supplement Market Regulation: Depression Claim, Undisclosed Drug, COVID Tincture

Executive Summary

FDA warns 10 businesses they’re marketing unapproved and misbranded drugs by making claims for supplements to treat depression. Supplement also found with one of, if not the most common violations in the US supplement market: it contained an undisclosed ED drug.

You may also be interested in...



Next US FDA Commissioner Will Have Opening To Fill In Dietary Supplement Programs Office

Steven Tave on 15 March will move from ODSP director to lead ORA’s Office of Strategic Planning and Operational Policy. Agency’s next commissioner, who Capitol Hill lobbyists say could be named next week, will appoint a replacement.

Amazon Flexes E-Commerce Heft By Imposing Quality-Control Requirements For Supplements

Amazon requires firms selling supplements on its site in the US to demonstrate their products comply with FDA regulations for labeling and GMPs. Marketers that don’t submit documentation face removal of their products from the site.

Amazon’s VMS Policy Mirrors US FDA Rules But May Reflect Stronger Industry Compliance

Amazon’s requirements reach to guaranteeing ingredients are compliant with FDA regulations. While the agency, for the most part, isn’t preventing sales of supplements containing ingredients that have not been notified as NDIs with proof of reasonable expectation of safety, Amazon could ask marketers for the information.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135866

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel